5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

A compound of formula (I-B):

• or a pharmaceutically acceptable salt thereof, wherein:
• X is NR3′ or CR3,
• Y is NR2 or CR4,
• wherein when X is NR3′ then Y is CR4, Y has a double bond to CR5, and X has a single bond to CR5;
• or when X is CR3 then Y is NR2, Y has a single bond to CR5, and X has a double bond to CR5;
• R2 is —H, C1-C3 alkyl, or C3-C6 cycloalkyl, wherein said C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and/or 1-6 deuterium atoms;
• R3 is —H, C1-C3 alkyl, C3-C6 cycloalkyl, halogen, or —CN;
• R3′ is —H, C1-C3 alkyl, —C3-C6 cycloalkyl, or —CN;
• R4 is —H, C1-C3 alkyl, or halogen, wherein said C1-C3 alkyl is optionally substituted with 1-3 fluorine atoms and/or 1-6 deuterium atoms;
• R5 is C6-C14 aryl or 5-to-10-membered heteroaryl, wherein said C6-C14 aryl or said 5-to-10-membered heteroaryl is optionally substituted with 1-5 R9 groups;
• R6 is —H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylene-NR7R8, C1-C6 alkylene-NR7′R8′, C1-C6alkylene-OH, C1-C6 alkylene-CN, C1-C2 alkylene-(C3-C6cycloalkylene)-(C0-C2 alkylene)-NR7R8, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-NR7′R8′, C1-C2 alkylene-(C3-C6 cycloalkylene)-(C0-C2 alkylene)-OH, C1-C2 alkylene-(4- to 8-membered heterocycloalkylene)-(C0-C2 alkylene)-NR7R8, C1-C2 alkylene-(4- to 8-membered heterocycloalkylene)-(C0-C2 alkylene)-NR7′R8′, C1-C2 alkylene-(C3-C7 heterocycloalkylene)-(C0-C2 alkylene)-NR7R8, or C1-C2 alkylene-(C3-C7 heterocycloalkylene)-(C0-C2 alkylene)-NR7′R8′, wherein the alkyl, alkylene, cycloalkyl, cycloalkylene, and heterocycloalkylene moieties in R6 are optionally substituted with 1-3 fluorine atoms and/or 1-6 deuterium atoms, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted with C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl;
• each R7 is independently —H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;
• each R8 is independently —H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 haloalkyl, C1-C6 alkylene-CN, or C1-C6 heteroalkyl;
• each pair of R7′ and R8′ taken together with the nitrogen atom to which they are attached independently form a 3- to 8-membered heterocyclic ring, wherein the heterocyclic ring optionally contains an additional 1-2 heteroatoms selected from the group consisting of N, O, and S, and wherein each heterocyclic nitrogen atom, if present, is independently optionally substituted with C1-C3 alkyl, C3-C6 cycloalkyl, C2-C3 haloalkyl, C2-C3 alkylene-CN, or C2-C3 heteroalkyl;
• each R9 is independently halogen, —OR10, —NR7R8, C1-C3 alkyl, C1-C3 haloalkyl, C3-C6 cycloalkyl, —CN, S(O)nC1-C3 alkyl, or S(O)nC3-C6 cycloalkyl,
• wherein n is an integer from 0 to 2;
• and
• each R10 is independently —H, C1-C3 alkyl, C1-C3 haloalkyl, or C3-C6 cycloalkyl, wherein said C1-C3 alkyl is optionally substituted with hydroxyl, C1-C3 alkoxy, and/or 1-6 deuterium atoms.